Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496263 | 0.92 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL496088 | 0.89 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL495876 | 0.88 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL2773467 | 0.87 | KDM4E (0.50) | CNR2CNR1 | |
| SCHEMBL7296606 | 0.86 | CNR2 (0.41) | CNR2CNR1LMNA | |
| SCHEMBL496487 | 0.85 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL497220 | 0.84 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL497046 | 0.84 | CNR2 (0.71) | CNR2CNR1 | |
| SCHEMBL496092 | 0.83 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL495832 | 0.82 | CNR2 (0.54) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012022865-A3 | DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY | Peugeot Citroën Automobiles SA (FR) | 2012-05-10 | — | — | WO | claimed |
| EP-1602658-B1 | Tricyclic pyrazole derivatives as cannabinoid receptor antagonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2011-12-07 | — | — | EP | claimed |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CENERX BIOPHARMA (US) | 2009-03-26 | — | — | US | claimed |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2005-12-22 | — | — | US | claimed |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) | 2012-04-12 | — | — | US | disclosed |
| US-8106218-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2012-01-31 | — | — | US | disclosed |
| EP-2230243-A1 | Pharmaceutical compounds | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-09-22 | — | — | EP | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-08-26 | — | — | US | disclosed |
| US-7485730-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2009-02-03 | — | — | US | disclosed |
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282798-A1 | Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation | CNR2, CNR1, GPR55 | CNR2 1/4885CNR1 2/4885LMNA 4074/4885 |
| US-20100215759-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885LMNA 4522/4885 |
| US-20120088751-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885LMNA 4207/4885 |
| US-20090081123-A1 | PHARMACEUTICAL COMPOUNDS | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885LMNA 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.